Zoetis Receives Positive Opinion from CVMP for Portela Veterinary Medicine Product

Zoetis has received a positive opinion from the Committee for Medicinal Products for Human Use (CVMP) for its Portela product. Zoetis specializes in animal health products, with a focus on companion animals (cats, dogs, and horses) and livestock (cattle, poultry, swine, fish, and other). The company's net sales are primarily generated from parasiticides, vaccines, dermatological products, anti-infectives, pain relievers, diagnostic products, medicated feed additives, and other categories.

Zoetis Inc. has received a positive opinion from the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) for Portela® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (OA) in cats Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats^[1]. If approved, Portela will be the first long-acting anti-nerve growth factor (NGF) mAb therapy for cats, designed to provide three months of OA pain relief with a single injection.

The CVMP's recommendation is based on a positive benefit-risk balance of the safety and efficacy data submitted. Clinical trials demonstrated that Portela is well tolerated, including by cats with kidney disease at IRIS stages 1, 2, or 3 Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats^[1]. The product targets NGF, a key mediator of OA pain, and has shown effectiveness in alleviating OA pain.

Rob Polzer, Ph.D., Executive Vice President and President, Research and Development at Zoetis, stated, "The CVMP’s positive opinion for Portela represents a significant step forward in advancing feline pain management. The long-acting antibody properties of Portela and its unique binding site to NGF will soon offer veterinarians and cat owners in the European Union a new option to alleviate pain associated with osteoarthritis, thereby helping to improve the quality of life for affected cats."

Osteoarthritis (OA) is a significant unmet medical need, affecting up to 40% of cats but only 18% are diagnosed by veterinary professionals . Portela offers a convenient, long-acting therapy to reduce OA pain, particularly beneficial for cats that are difficult to medicate regularly.

Zoetis continues to expand its OA pain franchise with Portela, joining Solensia® (frunevetmab), an anti-NGF mAb indicated for monthly alleviation of OA pain in cats, approved in over 40 countries Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats^[1]. Both products are designed to improve the quality of life for cats with OA pain.

The European Commission is expected to issue a decision based on the CVMP’s positive opinion during the fourth quarter of 2025, with Zoetis anticipating making Portela commercially available in the European Union in 2026 Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats^[1].

Zoetis, the world’s leading animal health company, generated revenue of $9.3 billion in 2024, with a focus on companion animals and livestock. Net sales are primarily generated from parasiticides, vaccines, dermatological products, anti-infectives, pain relievers, diagnostic products, medicated feed additives, and other categories Zoetis' Pain Relief Cat Medication Gets Recommendation for Marketing Approval in Europe^[2].